Compare Abeona Therapeutics Inc (ABEO) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard High Dividend Yield ETF — how do they compare? Abeona Therapeutics Inc trades at $7.43 (market cap $421.19M), while Vanguard High Dividend Yield ETF trades at $166.7. Which is the better fit depends on your goals.
| ABEO | VYM | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $166.14 |
52-Week Low | $4.17 | $136.63 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
VYM trades at $166.51, up 0.27% with a bullish technical signal from moving averages but overbought RSI readings. The ETF recently hit a new 52-week high and maintains strong institutional interest despite some position reductions. Recent news highlights VYM's role in retirement income strategies with a 2.2% dividend yield and decade-long performance comparisons to the S&P 500.
The outlook remains positive for income-focused investors given VYM's sustainable dividend growth and sector diversification. Key risks include potential underperformance versus growth indices and sensitivity to interest rate changes. Wall Street sentiment is generally favorable with the ETF positioned as a core holding for retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
